Device Trial Radar · NCT04398030
Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")
Last checked: Nov 20, 2026Latest source record: Aug 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Jul 17, 2020
Primary completion
Apr 22, 2021
Study completion Apr 22, 2021
Sponsor
- Lead sponsor
- Capillary Biomedical, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); AMCR Institute; Integrated Medical Development
- First posted
- May 21, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study has been designed as a prospectively enrolled, randomized sequence, 2-way crossover study of device performance, tolerability and safety of an investigational insulin infusion set using a coil-reinforced soft polymer indwelling cannula versus a commercial insulin infusion set using a soft Teflon indwelling cannula, during two 7-day home use periods with 4 in-clinic euglycemic clamp sessions during each of the 7-day periods. After a wash-out period, subjects will cross over into the investigational or control group, respectively.
Conditions
- Diabetes Mellitus, Type 1
- Type 1 Diabetes
Interventions
coil-reinforced soft polymer indwelling cannulaDevice
Insulin infusion set will be used for up to 7 days of continuous use or until failure
soft Teflon indwelling catheterDevice
Insulin infusion set will be used for up to 7 days of continuous use or until failure
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Primary Endpoint is the Rate of Decline (s) Over Wear Time (DOI, Day 3, Day 5, Day 7) of the Natural Logarithm of the Area Under the Glucose Infusion Rate Curve [ln (AUC0-300(GIR))].Time frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
AMCR Institute
Escondido, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.